Dr Kenneth Grossmann (IMAGE)

SWOG Cancer Research Network

Dr Kenneth Grossmann

Caption

Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery.

Credit

Huntsman Cancer Institute

Usage Restrictions

Include credit: Huntsman Cancer Institute

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.